1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid chloride | 1038695-04-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid chloride
• 英文别名: 1-(Cyclohexylmethyl)-2-oxo-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine-3-carbonyl chloride；1-(cyclohexylmethyl)-2-oxo-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine-3-carbonyl chloride
• CAS: 1038695-04-3
• 化学式: C₁₉H₂₆ClNO₂
• 分子量: 335.874
• InChiKey: XEGTWMZGFGVBQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid chloride 在 水 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成 2-[2-[[1-(Cyclohexylmethyl)-2-oxo-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine-3-carbonyl]amino]phenyl]acetic acid
  参考文献：
  名称：

  Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent

  摘要：

  The optimization of a series of 3-carbamoyl 2-pyridone derivatives as CB agonists is reported. These efforts resulted in the discovery of 3-(2-(1-(cyclohexylmethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-3-carboxamido)thiazol-4-yl)propanoic acid (21), a potent dual CB1/CB2 agonist without CNS side effects induced by CB1 receptor activation. It exhibited strong inhibition of scratching as a 1.0% acetone solution in the pruritic model. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.050
• 作为产物：
  描述：

  methyl 1-(cyclohexylmethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-3-carboxylate 在 草酰氯 、 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-cyclohexylmethyl-2-oxo-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carboxylic acid chloride
  参考文献：
  名称：

  Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent

  摘要：

  The optimization of a series of 3-carbamoyl 2-pyridone derivatives as CB agonists is reported. These efforts resulted in the discovery of 3-(2-(1-(cyclohexylmethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-3-carboxamido)thiazol-4-yl)propanoic acid (21), a potent dual CB1/CB2 agonist without CNS side effects induced by CB1 receptor activation. It exhibited strong inhibition of scratching as a 1.0% acetone solution in the pruritic model. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.050

文献信息

• Discovery of S-777469: An orally available CB2 agonist as an antipruritic agent
  作者：Masahide Odan、Natsuki Ishizuka、Yoshiharu Hiramatsu、Masanao Inagaki、Hiroshi Hashizume、Yasuhiko Fujii、Susumu Mitsumori、Yasuhide Morioka、Masahiko Soga、Masashi Deguchi、Kiyoshi Yasui、Akinori Arimura

  DOI：10.1016/j.bmcl.2012.02.072

  日期：2012.4

  The discovery of novel CB2 ligands based on the 3-carbamoyl-2-pyridone derivatives by adjusting the size of side chain at 1-, 5- and 6-position is reported. The structure–activity relationship around this template lead to the identification of S-777469 as a selective CB2 receptor agonist, which exhibited the significant inhibition of scratching induced by Compound 48/80 at 1.0 mg/kg po and 10 mg/kg

  据报道，通过调节1-，5-和6-位侧链的大小，发现了基于3-氨基甲酰基-2-吡啶酮衍生物的新型CB2配体。该模板周围的结构-活性关系导致鉴定出S-777469为选择性CB2受体激动剂，该化合物在1.0 mg / kg po和10 mg / kg po下表现出对化合物48/80诱导的刮擦的显着抑制作用（55 ％和61％）。
• CB 1/2 dual agonists with 3-carbamoyl 2-pyridone derivatives as antipruritics: Reduction of CNS side effects by introducing polar functional groups
  作者：Masahide Odan、Natsuki Ishizuka、Yoshiharu Hiramatsu、Masanao Inagaki、Hiroshi Hashizume、Yasuhiko Fujii、Susumu Mitsumori、Yasuhide Morioka、Masahiko Soga、Masashi Deguchi、Kiyoshi Yasui、Akinori Arimura

  DOI：10.1016/j.bmcl.2012.02.054

  日期：2012.4

  CB1 and CB2 receptors, suggesting the possibility of inducing psychoactive side effects through the CB1 receptor in the brain. To solve this issue, polar functional groups were introduced at the 3-position of the pyridone core of compound 1 to find CB1/2 dual agonists such as 17 and 20 which did not show any CNS side effects.

  我们的先导化合物1对CB1和CB2受体均显示出高亲和力，这表明可能通过大脑中的CB1受体诱导精神活性副作用。为了解决该问题，在化合物1的吡啶酮核心的3位引入极性官能团以发现CB1 / 2双重激动剂，例如17和20，它们没有显示任何CNS副作用。
• 3-CARBAMOYL-2-PYRIDONE DERIVATIVE
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1806342B1

  公开（公告）日：2013-04-17